Our investor proposition
GSK is a science-led global healthcare company that aims to deliver growth and improving returns to shareholders through the development of innovative pharmaceutical, vaccine and consumer healthcare products.
2021 Third quarter results announcement
New GSK Investor update
Emma Walmsley, CEO, and other members of CET hosted a virtual investor update on Wednesday 23 June.
The update provided a clear view of the strategy for New GSK, its outlook for growth and the opportunities we see for shareholder value creation.
Nick Stone appointed SVP Head of Investor Relations
Nick Stone has been appointed Head of Investor Relations, effective 4 October 2021.
Nick joins from AstraZeneca, where he has been leading Investor Relations in Europe, the Americas, and Asia Pacific, along with the sustainability outreach programme. Prior to this, he spent fifteen years in the biopharmaceutical sector, including in the areas of Commercial, Business Development and Corporate Strategy.
A qualified lawyer, Nick will lead IR for New GSK, working closely with the Consumer Healthcare IR team under Sonya Ghobrial in the run-up to the planned separation in mid-2022.